Risk-Management Assessment of Visible-Residue Limits in Cleaning Validation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Risk-Management Assessment of Visible-Residue Limits in Cleaning Validation
A risk-management assessment of visible-residue limits (VRL) in cleaning validation of pharmaceutical formulations was conducted for both pharmaceutical pilot plant and manufacturing facilities. The authors discuss how potential risks were identified, analyzed for probability, considered for seriousness, and controlled through avoidance or mitigation. These opportunities for VRL implementation then were identified for both pilot plant and manufacturing settings.


Pharmaceutical Technology


A risk-management assessment of VRL applications includes the identification of potential risks. The potential risk analysis determined the probability of occurrence and seriousness. Probabilities occur in low, medium, and high categories. Likewise, risk seriousness has designations of low, medium, and high. Individual risks populate a matrix of probability versus seriousness.

Risk evaluation leads to risk management. Risk avoidance takes the necessary steps to prevent a risk from occurring. Risk mitigation lessens the probability and seriousness of the risk. Risk acceptance is appropriate if the probability of occurrence is low or will not be serious enough to compromise product quality.

Risk identification


Risk analysis: key terminology
The most serious risk using VRLs is the potential that dirty equipment passes visual inspection and the subsequently manufactured formulation is compromised. Another risk is a regulatory agency challenge to the VRL approach. Finally, the subjectivity of visual assessment is a risk. The closer a VRL is to the ARL, the greater this risk becomes.

In addition to these risks, there are limitations when applying VRLs. To date, VRL determinations have been limited to stainless steel surfaces, which comprise the vast majority of equipment surfaces. Other materials of construction were not evaluated because of their poor reflective properties and would have to be addressed separately. VRL applications also have obvious limitations with respect to assessing microbiological control, particularly with wet-processing equipment. A cleaning-validation program would still need to assess the risks for microbial contamination of equipment. Surface sampling and rinse testing would be required to demonstrate a satisfactory state of control with respect to bioburden.

Risk analysis

Several causes are possible for dirty equipment passing visual inspection and compromising the subsequently manufactured formulation. The most likely scenario is that the inspector either did not perform a 100% inspection or performed an inadequate inspection on the equipment. As shown in Figure 1, the seriousness of an inadequate inspection is high because the subsequent batch could be compromised. The range of probability of an inadequate inspection depends on several factors. Training of the inspectors is a crucial component if VRLs are used to determine equipment cleanliness. Each active pharmaceutical ingredient (API) has a characteristic VRL, and inspectors must be familiar with the appearance of each residue. Visual inspection must be performed appropriately by inspecting all contact surfaces of the product with proper viewing angles of lighting and equipment. Documented training must be updated as new APIs and formulations are introduced into the manufacturing matrix.

VRLs resulting in residues above the ARL are a potential risk. A comparison of the VRL relative to the ARL is essential before any use of VRLs is initiated. The VRL must be lower than the ARL to use the VRL for cleaning evaluation. Although the seriousness for this risk is high, the probability is low.

The risk of a regulatory agency challenge is more likely when using VRLs only if there is not an initial validation study incorporating surface or rinsate testing. FDA has stated that the use of visual examination is limited between batches of the same product (2). Agencies from the European Union, Japan, and Canada also are likely to challenge a cleaning validation program using VRLs. The probability of an agency questioning the use of VRLs is high. The seriousness of the risk depends on the extent of VRL use and the data generated to support VRL use. VRL implementation can range from very specific situations, to more general applications, to the basis for an entire cleaning validation program. The data to support the use of VRL can range from a single, general limit (7, 8) to specific VRL determinations for each API and drug product (4, 6).

The subjectivity of VRL determinations and routine visual inspections are an ongoing risk. The probability and seriousness of this risk depend on the extent of training, ongoing monitoring, and VRL data generation, which can be minimized in a well-run VRL program by using at least four observers to determine VRLs and redundant monitoring, resulting in low probability and low seriousness.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here